(Q51498353)

5 April 2018

title

A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib. (English)

1 reference

5 April 2018

0 references

1 reference

Andrzej Mital

1

0 references

Janusz Limon

5

Janusz Limon

1 reference

5 April 2018

Krzysztof Lewandowski

3

Krzysztof Lewandowski

1 reference

5 April 2018

Andrzej Hellmann

6

Andrzej Hellmann

1 reference

5 April 2018

Bartosz Wasąg

4

Bartosz Wasąg

1 reference

5 April 2018

Anna M Piskorz

2

Anna Piskorz

1 reference

5 April 2018

publication date

7 April 2011

1 reference

5 April 2018

European Journal of Haematology

published in

1 reference

5 April 2018

volume

86

1 reference

5 April 2018

issue

6

1 reference

5 April 2018

page(s)

531-535

1 reference

5 April 2018

Diagnosis and treatment of systemic mastocytosis: state of the art.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01598.X

Mastocytosis: pathology, genetics, and current options for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01598.X

21 January 2018

Pediatric mastocytosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01598.X

Phenotypic and genotypic characteristics of mastocytosis according to the age of onset

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01598.X

Pathogenesis, clinical features, and treatment advances in mastocytosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01598.X

Biochemical markers predictive for bone marrow involvement in systemic mastocytosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01598.X

Recent advances in the understanding of mastocytosis: the role of KIT mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01598.X

The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01598.X

Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01598.X

A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01598.X

A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01598.X

Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01598.X

Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01598.X

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01598.X

Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01598.X

Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01598.X

Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01598.X

Dasatinib therapy for systemic mastocytosis: four cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01598.X

Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01598.X

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01598.X

10.1111/J.1600-0609.2011.01598.X

21 January 2018

Identifiers

DOI

1 reference

5 April 2018

1 reference

5 April 2018